BHF Advanced Training Fellow
We interweave the scientific fields of nanomedicince, biomaterials, tissue engineering, bioengineering and biochemistry to develop ‘personalised’ solutions based on light-mediated therapeutic modalities that utilise nanotechnology in treating many diseases such as cancer, wound healing, cardiovascular diseases, and central nervous system disorders. Our research interests include the novel synthesis of two-dimensional graphene-related nanosystems, controlled nanomedicine-based drug delivery platforms and mitochondria-targeted nanoassemblies through sub-cellular recognition processes. In the interdisciplinary space at the convergence of engineering, medicine and pharmaceutical nanotechnology, our research interests are broadly in the area of gas therapy for cardiovascular diseases. In collaboration with international colleagues, Dr. Tabish's research has primarily focussed on evaluating the pre-clinical efficacy of graphene-based nanomedicines in in-vitro, in-vivo and ex-vivo models of cancer and infections (see publications).
Our current research focuses on the role of nitric oxide in cardiovascular diseases and how endogenous and exogenous sources of nitric oxide can be manipulated for the treatment and prevention of cardiovascular diseases in a safe and targeted fashion. We also work in close collaboration with engineers, pharmacists, and clinicians to fabricate a novel first in class series of nanomedicines designed specifically to target cell's powerhouse 'mitochondria'. Targeting mitochondria with nanomedicines may represent a significantly important therapeutic target and potentially transform the conventional therapeutic interventions both philosophically and practically.
Graphene nanocomposites for real-time electrochemical sensing of nitric oxide in biological systems
Tabish TA. et al, (2023), Applied Physics Reviews, 10
Mitochondria-targeted nanomedicines for cardiovascular applications.
Tabish TA. and Lygate CA., (2023), Nanomedicine (London, England)